Inhibrx — Inhibrx Biosciences — Investor Presentation (March 2021)
33 slides from Inhibrx's investor presentation, March 2021
Slide 1: Innovation Driven Outcomes Focused
Innovation Driven Outcomes Focused March 2021
Slide 2: Presentation disclaimer
Presentation disclaimer The Company may not actually achieve the plans, intentions or expectations disclosed in its This presentation contains forward-looking statements. In some cases, you can forward-looking statements, and you should not place undue reliance on the Company’s identify forward-look
Slide 3: Key investment highlights
Key investment highlights Validation from industry leading partners Four clinical programs Proprietary single with upcoming readouts domain antibody (sdAb) platform Key financial highlights As of 2/28/2021 Common Fully Cash Stock Diluted $111.3M Outstanding Outstanding 37.8M 42.2M Potential rapid pa
Slide 4: Four differentiated clinical programs addressing large market opportunities
Four differentiated clinical programs addressing large market opportunities !" INBRX-109 INBRX-106 INBRX-105 INBRX-101 Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1x4-1BB tetravalent AAT-Fc fusion protein + Single agent activity in + Potential across numerous conditional agonist + Potential
Slide 5: Inhibrx's modular sdAb platform
Inhibrx’s modular sdAb platform Versatile and innovative formats enable validated Inhibrx multivalent formats complex target biology to be exploited Precision engineering 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa – Multivalent – precise valency selection engineered to specific target biology – Multispec
Slide 6: INBRX-109
INBRX-109 Tetravalent DR5 Agonist
Slide 7: Death receptor target overview
Death receptor 5 target overview Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related Valency apoptosis-inducing ligand (TRAIL) 2 4 >4 DR5 activation naturally eliminates damaged and neoplastic cells cancer cancer cancer Apoptosis Higher order clustering of DR5 is required to d
Slide 8: Valency drives DR5-mediated apoptosis
Valency drives DR5-mediated apoptosis Impact of valency on DR5 induced tumor cell death Antibody TRAIL INBRX-109 Tetravalent Anti-DR5 mAb (Bivalent) DR5 DR5 DR5 TRAIL (Trivalent) INBRX-109 (Tetravalent) cancer cancer cancer healthy healthy healthy INBRX-109 is 100x more potent in preclinical Weak Mo
Slide 9: INBRX-109 engineered to avoid hepatotoxicity
INBRX-109 engineered to avoid hepatotoxicity Therapeutic format selection designed to balance efficacy and safety Human hepatocyte toxicity assay TAS266 TAS266 INBRX-109 INBRX-109 Hex-1F5 Hepatocytes may be subject to on-target toxicity for DR5 pathway agonism + Previous tetravalent DR5 agonist failed
Slide 10: Ph1 INBRX-109 trial design and status
Ph1 INBRX-109 trial design and status First in human Phase 1 trial started Nov. 2018 PART 1: PART 2: Dose expansion PART 3: Dose escalation cohorts Combination studies completed ongoing 0.3 to 30 mg/kg Initial expansion cohort indications were selected based on in vitro and ongoing in vivo sensitivi
Slide 11: Fast to market opportunity
Fast to market opportunity Chondrosarcoma Incidence rate PFS from failed study of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) ~1,400 Efficacy data PFS 3.7 mo vs 2.9 mo Placebo cases per year Comment Negative study No approved therapeutic for t
Slide 12: INBRX-109 data and registration-enabling study design in chondrosarcoma
INBRX-109 data and registration-enabling study design in chondrosarcoma INBRX-109 in chondrosarcoma: Potential registration-enabling study design: Randomized, double-blind, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma Randomization Conventi
Slide 13: INBRX-106
INBRX-106 Hexavalent OX40 Agonist
Slide 14: INBRX-106 hexavalent OX40 agonist
INBRX-106 hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells OX40: sdAb OX40: sdAb Hexavalent engagement of OX40: • Provides co-stimulation to activated T-cells OX40: sdAb OX40: sdAb • Reverses regulatory T-cell induced immune suppression OX40: sdAb OX40: sdAb • Enhances
Slide 15: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist Valency Isotype Ligand blocking Candidates Status MOXR-0916 Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) Bi- IgG1 Y INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discontinued Bi- IgG2 Y PF-04518600 Disco
Slide 16: Valency drives OX40 agonism
Valency drives OX40 agonism CD4+ T cell proliferation Bivalent INBRX-106 anti-OX40 Hexavalent Ox40 OX40 INBRX-106 Bivalent anti-OX40 Weak OX40 Strong OX40 signaling signaling • Suboptimal TCR stimulation can be enhanced through OX40 agonism • INBRX-106 outperformed bivalent agonist 16
Slide 17: Hexavalent OX40 agonism potently induces anti-tumor immune activation
Hexavalent OX40 agonism potently induces anti-tumor immune activation Hexavalent OX40 agonism impacts T-cell populations to tip the balance toward tumor eradication Redmond lab 17 Earle A. Chiles Research Institute Providence Cancer Institute
Slide 18: OX40 agonism amplifies T-cell function when combined with PD1 blockade
OX40 agonism amplifies T-cell function when combined with PD1 blockade T-cell function can be enhanced through combined PD1 blockade and OX40 agonism 18
Slide 19: Phase 1 INBRX-106 trial design and status
Phase 1 INBRX-106 trial design and status First in human Phase 1 trial started December 2019 PART 3: Dose escalation PART 1: Single agent dose escalation with Keytruda™ Completed Dose Level Notable Prior Therapies and Best Best Response Notable Time on mg/kg Demographics Tumor Type Response RECIST T
Slide 20: INBRX-105
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 21: INBRX-105 is a tumor-targeted 4-1BB agonist
INBRX-105 is a tumor-targeted 4-1BB agonist PD-L1: sdAb INBRX-105 is designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression Highly expressed on tumor infiltrating immune cells, 4-1BB 4-1BB: sdAb signaling promotes prolonged T-cell survival memory formation Fc Effector Co
Slide 22: Focusing 4-1BB agonism to improve therapeutic index
Focusing 4-1BB agonism to improve therapeutic index INBRX-105 selectively agonizes 4-1BB at sites of PD-L1 expression • The tumor selective antigen, PD-L1, acts as an anchor to cluster 4-1BB binding VHHs • PD-L1 indicates ongoing tumor inflammation, but is insufficient to predict response to checkpo
Slide 23: An INBRX-105-like surrogate drives robust tumor T-cell expansion and anti-tumor activity
An INBRX-105-like surrogate drives robust tumor T-cell expansion and anti-tumor activity Single agent study Enhancement of tumor infiltrating T-cells Combination study w/ PD1 antagonist – Low dose of INBRX-105 + an optimal dose of anti-PD1 is highly synergistic 23 4-1BB agonism drives enhanced CD8+
Slide 24: Phase 1 INBRX-105 trial design and status
Phase 1 INBRX-105 trial design and status First in human Phase 1 trial started Feb. 2019 PART 1: PART 2: PART 3: PART 4: Dose escalation Dose expansion Dose escalation Dose expansion Completed initiated planned planned INBRX-105 INBRX 105 INBRX-105 + Keytruda™ INBRX-105 + Keytruda™ Locally advanced
Slide 25: INBRX-101
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 26: AATD and current therapy shortcomings
AATD and current therapy shortcomings What is AATD? AATD standard of care AATD is an orphan respiratory Current therapy is sub-optimal inherited disease Plasma derived AAT with weekly infusions is Increases risk of developing pulmonary not able to maintain normal serum AAT levels disease, resulting
Slide 27: INBRX-101 optimizing AAT augmentation therapy
INBRX-101 optimizing AAT augmentation therapy Elimination of oxidation-prone residues INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein AAT • Potential to extend the dosing range, from weekly to every three weeks, while maintaining patients in the normal range of AAT exposu
Slide 28: INBRX-101: first human pharmacokinetic data
INBRX-101: first human pharmacokinetic data PK profile of first 5 patients: 10 mg/kg INBRX-101 10 Serum AAT level (μM) Preliminary human PK data for first five subjects dosed with 10 mg/kg single IV dose of INBRX-101 1 • Consistent with preclinical estimates • Estimated human half-life is approximat
Slide 29: Near term expected clinical milestones
Near term expected clinical milestones INBRX-109 (DR5) INBRX-101 (AAT) Initiation of chondrosarcoma Phase 1 data registration-enabling trial INBRX-106 (OX40) / Keytruda INBRX-109 (DR5) dose expansion cohort data INBRX-105 (PDL- initial pancreatic 1x41BB) Keytruda and mesothelioma INBRX-105 (PDL-1x41
Slide 30: Inhibrx contact details
11025 N. Torrey Pines Rd, Ste 200 La Jolla, CA 92037 www.inhibrx.com
Slide 31: Supplementary Slides
Supplementary Slides
Slide 32: INBRX-109 preliminary efficacy in malignant pleural mesothelioma, epithelioid subtype
INBRX-109 preliminary efficacy in malignant pleural mesothelioma, epithelioid subtype 32
Slide 33: INBRX-109 - favorable adverse event (AE) profile
INBRX-109 - favorable adverse event (AE) profile AE Term AE related to INBRX-109 Grade per CTCAEv5.0 Gr 1&2 (N) Gr 3 (N) All Grade (N) Fatigue 16 1 17 ALT increased 8 3 11 AST increased 9 2 11 Nausea 7 1 8 Diarrhea 7 0 7 Pyrexia 5 0 5 Abdominal pain 3 1 4 Rash 3 0 3 Headache 3 0 3 Decreased appetite
Inhibrx Biosciences — Investor Presentation (March 2021) on 6ix